INNA CHERNOGLAZ: Open Payments
NPI 1225226756 · BROOKLYN, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$603 in 29 payments from 12 companies in 2025. Trend: 2023 $855 · 2024 $1,202 · 2025 $603
Food & beverage: $603
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 8 | $151 |
| Novo Nordisk Inc | 5 | $110 |
| Esperion Therapeutics, Inc. | 4 | $85 |
| Astellas Pharma US Inc | 2 | $54 |
| Amgen Inc. | 2 | $45 |
| Sumitomo Pharma America, Inc. | 2 | $34 |
| Abbott Laboratories | 1 | $26 |
| Ardelyx, Inc. | 1 | $24 |
| Aimmune Therapeutics, Inc. | 1 | $24 |
| Vifor Pharma, Inc. | 1 | $19 |
Products named: NEXLETOL, LINZESS, Ozempic, Veozah, UBRELVY, GEMTESA, CREON, FREESTYLE LIBRE 3.
Industry payments across NY — which companies pay providers there.
